Equity InsiderGovernments Are Racing to Rebuild Encryption Before Quantum Computers Break It, and a Canadian Company Is Taking Its Toolkit to Southeast AsiaEquity Insider•13 min read
Equity InsiderA $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill ItEquity Insider•12 min read
Equity InsiderThe West Wants a Critical-Minerals Supply Chain Outside China. One Nasdaq Company Is Trying to Build a Piece of It in Greenland.Equity Insider•12 min read
UncategorizedA Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics OpportunityEquity Insider•11 min read
Equity InsiderFusion Was a Punchline – General Fusion Heated Plasma to 8.4 Million Degrees by Squeezing ItEquity Insider•23 min read
Equity InsiderFrom the Lab to the Grid: General Fusion Signs a Framework to Bring Fusion Power to ItalyEquity Insider•18 min read
Equity InsiderThe Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for ItEquity Insider•10 min read
Equity InsiderVisionWave Holdings, Inc. Announces Filing of U.S. Provisional Patent Application for SDNN™ Symbiotic Deep Neural Network Architecture for Autonomous Defense and Intelligent SystemsEquity Insider•15 min read
Equity Insider16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart GapEquity Insider•13 min read
Equity InsiderThe Quiet Bottleneck in AI Drug Discovery Isn't the Model — It's the Biology Underneath ItEquity Insider•13 min read
Equity InsiderA Wartime Tungsten Mine the U.S. Government Wanted Drilled — but Never Did — Just Changed HandsEquity Insider•14 min read
Equity InsiderThe Frontier Goes Public — and the Whole Sector Comes With ItEquity Insider•11 min read
Equity InsiderAfter CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune CellEquity Insider•11 min read
Equity InsiderA Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus Issued on behalf of Conexeu Sciences Inc.Equity Insider•13 min read
